PharmaDrug Inc CEO Daniel Cohen tells Proactive it has successfully completed the fabrication of a novel medical device capable of delivering sustained, low quantities of a tryptamine-based pharmaceutical to the front of the eye, with the intended purpose to potentially lower intraocular pressure in patients suffering from glaucoma. Additionally, the company said a head-to-head drug elution study of its three undisclosed DMT-analogue candidates has now been completed while supportive cell-based biocompatibility has been examined for all three candidate molecules.
PharmaDrug advances DMT-analogue glaucoma program with fabrication of medical device
